-

Aphios Awarded NIH Grant For Development of a Double-Encapsulated mRNA Vaccine for COVID-19 and Other Diseases

WOBURN, Mass.--(BUSINESS WIRE)--Aphios announced today that it was awarded an NIH grant to develop a double encapsulated mRNA vaccine for COVID-19 and other diseases.

COVID-19 has cost the US more than a million lives, significant social upheaval and human suffering and over $16 trillion in treasury. COVID-19 has quickly become the most impactful healthcare, social, and economic crisis of our lifetime. The need for cold storage, requirement for boosters and potential for adverse allergic reactions are major drawbacks of current COVID-19 vaccines. Due to the relatively short-lived persistence of antibodies to coronavirus estimated to be in the range of a few months and the endemic nature of the virus, mRNA vaccination could become a recurring and critical healthcare and economic necessity for COVID-19 and other diseases.

Aphios was awarded a Phase I Small Business Innovation Research (SBIR) grant to develop a single-shot, room-temperature stable, double-nanoencapsulated mRNA vaccine for COVID-19. The mRNA molecule that encodes the coronavirus Spike protein will be first nanoencapsulated in lipid nanoparticles (LPN) and then into biodegradable polymer nanospheres (PNS). The release of the mRNA LPN vaccine will be controlled by PNS degradation. Thus, mRNA LPN will remain in the body longer and will sustain the persistence of antibodies to the coronavirus. Additionally, double-encapsulation of the mRNA vaccine construct in PNS will protect the lipid mRNA nanoparticle from degradation and increase shelf stability at room and refrigerator temperatures. The double-nanoencapsulation technology will be readily applicable to mRNA vaccines for different COVID-19 variants and other diseases.

About Aphios Corporation:

Aphios (www.aphios.com) is a clinical stage, green biotechnology company developing enabling technology platforms to improve drug discovery and manufacturing, nanotechnology drug delivery and pathogenic safety. Based on these platforms, Aphios is developing enhanced therapeutics to prevent disease, maintain health, improve quality-of-life and treat chronic diseases including cancers and supportive care, infectious diseases such as HIV/AIDS, influenza and COVID-19, and central and peripheral nervous system disorders in an environmentally sustainable manner.

Research reported in this press release was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R43AI165352. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Contacts

Trevor P. Castor, Ph.D., CEO
(001) 781-858-7520
tcastor@aphios.com

Aphios


Release Summary
Aphios announced today that it was awarded an NIH grant to develop a double encapsulated mRNA vaccine for COVID-19 and other diseases.
Release Versions

Contacts

Trevor P. Castor, Ph.D., CEO
(001) 781-858-7520
tcastor@aphios.com

Social Media Profiles
More News From Aphios

Aphios Granted US Patent for Thermal Conversion of CBDA and Other Carboxylic Acid Cannabinoids

NORTH READING, Mass.--(BUSINESS WIRE)--Aphios announced today that it was granted US Patent No. 11,981,174 for the thermal conversion of CBDA to CBD and other carboxylic acid cannabinoids to cannabinoids. The patent was granted for a process to improve the manufacturing of pharmaceutical grade CBD and other cannabinoids following current Good Manufacturing Practices (cGMP) of the US FDA. The major cannabinoids in marijuana (Cannabis) originate from cannabigerolic acid (CBGA) and are converted b...

Aphios Awarded NIH SBIR Grant For Development of Anti-CCR5 Nanoparticles to Treat Alzheimer’s Disease

NORTH READING, Mass.--(BUSINESS WIRE)--Aphios announced today that it was awarded an NIH SBIR grant from the National Institute on Aging (NIA) to develop anti-CCR5 nanoparticles to treat Alzheimer’s disease. Alzheimer's disease and dementia are debilitating diseases affecting over 6.7 million people in the United States and over 55 million people worldwide. Alzheimer's disease has been characterized by multiple factors, including but not limited to amyloid plaque formation, tau protein entangle...

Aphios Corporation Granted Japanese Patent for Novel Compositions to Treat Folic Acid Deficiency and Morning Sickness

NORTH READING, Mass.--(BUSINESS WIRE)--Aphios Corporation announced today that it has been granted Japanese Patent No. 7,520,838 for novel compositions to treat folic acid deficiency and morning sickness. The dosage forms have an effective amount of a folic acid, gingerols and shogaols to suppress nausea, relieve gastric distress and promote hematopoiesis. Pregnancy related nausea and vomiting (PRNV) is the most common medical condition during pregnancy. PRNV affects up to 70% of women during t...
Back to Newsroom